Glazer Capital’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
Other funds holding APLS
Glazer Capital's APLS Position: Q2 2026 in Review
Glazer Capital sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 1,294,196 shares — an estimated $52.1M sold.
Glazer Capital first reported a position in APLS in Q1 2026 and held it in 1 quarter. The position peaked at $52.1M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Glazer Capital reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Glazer Capital sold 1,294,196 Apellis Pharmaceuticals shares in Q2 2026, an estimated $52.1M.
- Glazer Capital first reported a position in Apellis Pharmaceuticals in Q1 2026 and held it in 1 quarter.
- Glazer Capital's Apellis Pharmaceuticals position peaked at $52.1M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Glazer Capital's 13F filing for Q2 2026, filed 17 Aug 2026.